Pharmaceutical News

RSS

A century of safety: Aluminium vaccine adjuvants do not raise serious long-term health risks

A BMJ systematic review of 59 human studies found no evidence supporting causal links between aluminum-adjuvanted vaccines and serious or long-term outcomes such as autism spectrum disorder, asthma, autoimmune conditions, or other chronic illnesses. The most consistent adverse events were uncommon, local, self-limited persistent nodules or granulomas, likely reflecting delayed-type hypersensitivity.

11 May 2026

Study compares two antibiotics in treating severe hemorrhagic bacterial pneumonia

Stenotrophomonas maltophilia (S. maltophilia) is a multidrug-resistant bacterium that can cause severe and life-threatening hemorrhagic pneumonia in individuals with weakened immune systems.

11 May 2026

Semaglutide shows sustained weight loss benefits in older adults

A new analysis of the STEP trails carried out by semaglutide manufacturer Novo Nordisk has analysed various trials to show the safety and efficacy of the obesity drug semaglutide in older adults (over 65 years), and found similar efficacy and safety as in the general trial populations .

11 May 2026

Daily orforglipron treatment reduces weight and blood sugar in seniors

A new analysis to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial programme population.

11 May 2026

Greater weight loss from GLP-1 drugs lowers health complication risk

New research to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) shows that, following treatment for obesity or diabetes or both using incretin-based drugs, losing more weight versus less weight, and losing a little weight versus gaining weight, both lead to relatively lower risk of obesity-related conditions.

10 May 2026

Liver fat may disrupt post-meal glucagon control in early type 2 diabetes

Researchers found that MASLD, rather than type 2 diabetes alone, was linked to higher fasting glucagon levels in adults with newly diagnosed diabetes and matched controls. In people with early type 2 diabetes, higher liver fat was specifically associated with exaggerated early post-meal glucagon responses, independent of insulin sensitivity, visceral fat, amino acids, or NEFAs.

10 May 2026

Asthma medication formoterol shows promise for treating fatty liver disease

MUSC researchers are tackling MASH, or metabolic dysfunction-associated steatohepatitis, a liver disease affecting hundreds of millions worldwide.

8 May 2026

GLP-1 drugs may reshape how brain values rewarding foods

A new study from the University of Virginia reveals that a widely used class of weight-loss drugs does more than suppress appetite-it directly alters brain circuits that control motivation and reward.

6 May 2026

CGRP inhibitors may reduce glaucoma risk among migraine patients

A type of drug used to prevent migraine may be associated with a reduced risk of glaucoma, according to a study published May 6, 2026, in Neurology®, the medical journal of the American Academy of Neurology.

6 May 2026

Popular GLP-1 drugs significantly reduce major cardiovascular events,

Researchers evaluate the long-term cardiovascular safety and efficacy of GLP-1RAs in high-risk populations.

6 May 2026

GLP-1 use surges as surgery rates drop for severe obesity

Drawing on electronic health records from nearly 20 million patients with severe obesity, researchers from University of California San Diego find that GLP-1 prescriptions have grown exponentially -- from less than 4,600 prescriptions in 2018 to more than 1.4 million in 2025 -- according to a new real-world analysis presented today at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

Study highlights stigma surrounding popular GLP-1 weight loss drugs

Glucagonlike peptide-1 (GLP-1) medications have taken over the national conversation around weight loss.

4 May 2026

Five-target drug beats GLP-1/GIP therapy in obese diabetic mice

A Nature study reports a single-molecule GLP-1–GIP–lanifibranor quintuple agonist that targets incretin receptor-expressing cells while activating PPARα/γ/δ pathways. In obese and insulin-resistant mice, the compound reduced body weight, food intake, and hyperglycaemia more effectively than semaglutide or GLP-1R–GIPR co-agonism, while remaining a preclinical finding.

30 Apr 2026

GLP-1 drugs reduce risk of major adverse cardiovascular events

New research has shown that GLP‑1 weight-loss drugs deliver protection against heart attacks, strokes and premature death over a sustained period of time.

30 Apr 2026

Antibiotic minocycline shows potential for treating panic disorder symptoms

A study supported by FAPESP shows that small doses of the antibiotic minocycline may help treat panic disorder.

30 Apr 2026

Emergency settings more likely to initiate risky medications for seniors

Initial prescriptions for medications affecting cognition, such as antipsychotics, are disproportionately likelier to come from acute and post-acute settings such as emergency rooms, hospitals and skilled nursing facilities than they are from doctors' offices, new UCLA research suggests.

28 Apr 2026

GLP-1 drugs promise wider health benefits, but experts urge caution on use

GLP-1 receptor agonists are reshaping care for type 2 diabetes, obesity, chronic kidney disease, and obstructive sleep apnea, with evidence for glycemic, weight-loss, cardiovascular, and renal benefits. The review urges nurse practitioners to balance expanding clinical promise with careful prescribing, patient education, monitoring, access advocacy, and vigilance for gastrointestinal, endocrine, pregnancy-related, and rare serious risks.

27 Apr 2026

GLP-1 weight loss is driven mainly by fat loss, not muscle loss

GLP-1-based therapies helped adults with overweight or obesity lose weight mainly by reducing fat mass and visceral adipose tissue, while lean body mass losses were generally modest. The findings suggest these treatments can support higher-quality weight loss when paired with individualized care, nutrition, and resistance training.

27 Apr 2026

Apixaban reduces complications, helps older adults spend more time at home after blood clots

Older adults recovering from serious blood clots often face long periods of hospitalization or rehabilitation due to a higher rate of recurrence.

27 Apr 2026

Brain injury survivors use psychedelics to manage symptoms

A new study from the University of Victoria (UVic) has identified a segment of traumatic brain injury survivors who are using psychedelics to self-medicate for cognitive, mood and somatic symptoms such as headaches.

27 Apr 2026